Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT04970043
Status
Unknown

Conditions

  • Lung Cancer Stage II

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab+ pemetrexed + platinum — DRUG
    Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle. Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed. Maintenance treatment period: Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle. Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years).

Study Details

A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients

Key Dates

Start date
Jul 31, 2021
Status verified
Jul 2021
Primary completion
Jul 30, 2024
Completion
Jul 30, 2024

Study Design

Enrollment
58 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab+ pemetrexed + platinum

Primary Outcome Measure

Progression-free survival [ Time Frame: 1 Year ]

Central Contacts

Related Studies